Votre Partenaire en Modélisation & Simulation Pharmacocinétique !

PhinC met en place la meilleure stratégie de Modélisation & Simulation pour orienter les étapes clefs de votre développement et optimiser ses coûts.
Les services PhinC
Nos actualités
Formation gratuite : sécurisez et optimisez votre développement

Actualités

Formation gratuite : sécurisez et optimisez votre développement

📣Inscrivez vous à notre formation gratuite ⬇ … 𝗦𝗲́𝗰𝘂𝗿𝗶𝘀𝗲𝘇 𝗲𝘁 𝗼𝗽𝘁𝗶𝗺𝗶𝘀𝗲𝘇 𝗹𝗲 𝗱𝗲́𝘃𝗲𝗹𝗼𝗽𝗽𝗲𝗺𝗲𝗻𝘁 𝗱𝗲 𝘃𝗼𝘁𝗿𝗲 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁 𝗺𝗲́𝗱𝗶𝗰𝗮𝗺𝗲𝗻𝘁 !
Lire la suite

Ils nous font confiance

Pascal Benderitter
Pascal Benderitter
Senior Program Director NCX - Oncodesign Precision Medicine
In the frame of the preclinical development of our main asset, we have been looking after experts in the modeling of pharmacokinetics. Working with PhinC, a member of the AFFSSI, has only seemed natural in regards with their recognized expertise and by a common vision of long-term collaboration. Their work on a PBPK model was a clear added value in the regulatory filing and contributed to the approval of the clinical trial application early 2023. We are happy to count them among the key players in the ongoing clinical study on ODS-101.
Sakina Sayah-Jeanne
Sakina Sayah-Jeanne
Senior Director, Translational R&D - Da Volterra
PhinC has been accompanying Da Volterra for several years on PBPK Modelling activities. Our collaboration, based on mutual trust, has already been very fruitful and has allowed Da Volterra to gain precious knowledge on its product under development. Da Volterra enjoys working with PhinC and will continue to do so in the years to come, leaning from its expertise.
Agnes Hemon
Agnes Hemon
Preclinical and PK Clinical Officer - HRA Pharma
PhinC is one of HRA Pharma’s valuable partners for pharmacokinetic studies. From just advice to modeling, we know we can trust them to efficiently support and carry out our projects.
Antoine Tarral
Antoine Tarral
Head of HAT Clinical Programme - DNDi
The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program.
Club Phase 1
GMP - Groupe de Métabolisme et Pharmacocinétique
EUFEMED
AFSSI
MabDesign
Oncodesign services
Paris Saclay
Paris Region Business Club
Medicen
French Tech Paris-Saclay
Genopole